Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.85
-0.05 (-0.85%)
At close: Jun 27, 2025, 4:00 PM
6.13
+0.28 (4.79%)
After-hours: Jun 27, 2025, 7:41 PM EDT
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$460,638
Profits / Employee
-$2,141,954
Market Cap
97.84M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8 | 0 | - |
Dec 31, 2023 | 8 | 2 | 33.33% |
Dec 31, 2022 | 6 | 0 | - |
Dec 31, 2021 | 6 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
COYA News
- 10 days ago - Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025 - Business Wire
- 26 days ago - Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations - Business Wire
- 6 weeks ago - Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Business Wire
- 6 weeks ago - Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - Business Wire
- 7 weeks ago - Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - Business Wire
- 7 weeks ago - Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors - GlobeNewsWire
- 2 months ago - Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
- 2 months ago - Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Business Wire